SCHEMBL10304992

SCHEMBL10304992

CCOc1nc(-c2cc(OC)ccc2C)cs1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP1A1 P04798 2/20 0.45
▸ CYP1B1 Q16678 2/20 0.45
▸ L3MBTL1 Q9Y468 1/20 0.44
▸ CYP19A1 P11511 1/20 0.43
▸ MEN1 O00255 5/20 0.41
▸ KMT2A Q03164 5/20 0.41
▸ NPC1 O15118 4/20 0.41
▸ GAA P10253 2/20 0.40
▸ MAPT P10636 6/20 0.40
▸ SMN1; SMN2 Q16637 5/20 0.40
▸ RAB9A P51151 3/20 0.40
▸ NFKB1 P19838 2/20 0.40
▸ NFKB2 Q00653 2/20 0.40
▸ RELA Q04206 2/20 0.40
▸ ATM Q13315 1/20 0.40
▸ HTT P42858 2/20 0.39
▸ KDM4E B2RXH2 2/20 0.38
▸ ALDH1A1 P00352 2/20 0.38
▸ THRB P10828 1/20 0.38
▸ PTGS2 P35354 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10305109 0.87 CYP1A1 (0.50) CYP1A1CYP1B1L3MBTL1CYP19A1MEN1
SCHEMBL15624619 0.85 CYP1A1 (0.44) CYP1A1CYP1B1L3MBTL1CYP19A1MEN1
SCHEMBL10305054 0.79 ATP4A (0.48) CYP19A1NPC1GAAMAPTSMN1; SMN2
SCHEMBL10304965 0.74 BTK (0.43) MEN1KMT2ANPC1GAAMAPT
SCHEMBL10304993 0.74 MEN1 (0.51) CYP1A1CYP1B1CYP19A1MEN1KMT2A
SCHEMBL10305107 0.73 CYP11B1 (0.45) NPC1GAARAB9AHTTKDM4E
SCHEMBL10304933 0.72 MAPT (0.43) MEN1KMT2ANPC1GAAMAPT
SCHEMBL10304990 0.71 HSP90AA1 (0.47) CYP1A1CYP1B1MEN1KMT2ANPC1
SCHEMBL10305106 0.71 MAPT (0.40) MEN1KMT2AMAPTSMN1; SMN2ATM
SCHEMBL10305015 0.69 PDE2A (0.42) MEN1KMT2ANPC1GAAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120264770-A1 HSP90 INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-10-18 — — US disclosed
US-20120172321-A1 HSP90 INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-07-05 — — US disclosed
US-20090305998-A1 HSP90 INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-12-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090305998-A1 HSP90 INHIBITORS HSP90AB1, HSP90AA1, HSP90B1 CYP1A1 2326/4885CYP1B1 1917/4885L3MBTL1 4161/4885
US-20120264770-A1 HSP90 INHIBITORS HSP90AB1, HSP90AA1, HSP90B1 CYP1A1 2326/4885CYP1B1 1917/4885L3MBTL1 4161/4885
US-20120172321-A1 HSP90 INHIBITORS HSP90AB1, HSP90AA1, HSP90B1 CYP1A1 2326/4885CYP1B1 1917/4885L3MBTL1 4161/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback